ECSP099722A - Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer - Google Patents
Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncerInfo
- Publication number
- ECSP099722A ECSP099722A EC2009009722A ECSP099722A ECSP099722A EC SP099722 A ECSP099722 A EC SP099722A EC 2009009722 A EC2009009722 A EC 2009009722A EC SP099722 A ECSP099722 A EC SP099722A EC SP099722 A ECSP099722 A EC SP099722A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- pirimidina
- pirido
- ona
- pi3k
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
La invención se refiere a compuestos de la fórmula I: Iy sus sales o solvatos farmacéuticamente aceptables, así como a métodos de preparación y uso de los compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91116007P | 2007-04-11 | 2007-04-11 | |
PCT/US2008/004807 WO2008127712A1 (en) | 2007-04-11 | 2008-04-11 | Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP099722A true ECSP099722A (es) | 2009-12-28 |
Family
ID=39642739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2009009722A ECSP099722A (es) | 2007-04-11 | 2009-11-09 | Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer |
Country Status (26)
Country | Link |
---|---|
US (2) | US20100209340A1 (es) |
EP (1) | EP2142544B8 (es) |
JP (1) | JP2010523681A (es) |
KR (1) | KR20090130104A (es) |
CN (1) | CN101711249A (es) |
AU (1) | AU2008239596B2 (es) |
BR (1) | BRPI0810175A2 (es) |
CA (1) | CA2683820A1 (es) |
CO (1) | CO6241119A2 (es) |
CR (1) | CR11098A (es) |
DO (1) | DOP2009000242A (es) |
EA (1) | EA018964B1 (es) |
EC (1) | ECSP099722A (es) |
ES (1) | ES2425068T3 (es) |
HK (1) | HK1139941A1 (es) |
IL (1) | IL201209A0 (es) |
MA (1) | MA31336B1 (es) |
MX (1) | MX2009010815A (es) |
MY (1) | MY150747A (es) |
NI (1) | NI200900183A (es) |
NZ (1) | NZ579945A (es) |
SV (1) | SV2009003389A (es) |
TN (1) | TN2009000389A1 (es) |
UA (1) | UA101315C2 (es) |
WO (1) | WO2008127712A1 (es) |
ZA (1) | ZA200906648B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006065703A1 (en) * | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
BRPI0617159B8 (pt) * | 2005-10-07 | 2021-05-25 | Exelixis Inc | compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo |
JP5270353B2 (ja) * | 2005-10-07 | 2013-08-21 | エクセリクシス, インク. | ホスファチジルイノシトール3−キナーゼインヒビターとその使用方法 |
AU2007284562B2 (en) | 2006-08-16 | 2013-05-02 | Exelixis, Inc. | Using PI3K and MEK modulators in treatments of cancer |
WO2008032162A1 (en) | 2006-09-15 | 2008-03-20 | Pfizer Products Inc. | Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors |
UA100979C2 (ru) | 2007-04-10 | 2013-02-25 | Экселиксис, Инк. | Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака |
EP2142543B8 (en) * | 2007-04-11 | 2013-07-03 | Exelixis, Inc. | Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer |
PA8843901A1 (es) * | 2008-09-30 | 2010-05-26 | INHIBIDORES DE PIRIMIDINONA DE PI3K( ALFA) Y m TOR | |
US20120040950A1 (en) * | 2009-12-22 | 2012-02-16 | Vertex Pharmaceuticals Incorporated | Isoindolinone inhibitors of phosphatidylinositol 3-kinase |
TW201139436A (en) | 2010-02-09 | 2011-11-16 | Exelixis Inc | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors |
WO2012037204A1 (en) | 2010-09-14 | 2012-03-22 | Exelixis, Inc. | Inhibitors of pi3k-delta and methods of their use and manufacture |
WO2013056067A1 (en) * | 2011-10-13 | 2013-04-18 | Exelixis, Inc. | Compounds for use in the treatment of basal cell carcinoma |
CN107375289A (zh) | 2011-11-01 | 2017-11-24 | 埃克塞利希斯股份有限公司 | 用于治疗淋巴组织增生性恶性肿瘤的作为磷脂酰肌醇3‑激酶抑制剂的化合物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2937284A (en) * | 1958-05-01 | 1960-05-17 | Burroughs Wellcome Co | 2, 4-diamino-5, 6-dialkylpyrido (2, 3-d) pyrimidines and method |
IL117923A (en) * | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
US7019002B2 (en) * | 2001-12-11 | 2006-03-28 | Pharmacia & Upjohn, S.P.A. | Pyridopyrimidinones derivatives as telomerase inhibitors |
US20080255162A1 (en) * | 2004-05-04 | 2008-10-16 | Warner-Lambert Company Llc | Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents |
CA2624965A1 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of pi3k.alpha. |
BRPI0617159B8 (pt) * | 2005-10-07 | 2021-05-25 | Exelixis Inc | compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo |
AU2007284562B2 (en) * | 2006-08-16 | 2013-05-02 | Exelixis, Inc. | Using PI3K and MEK modulators in treatments of cancer |
WO2008032162A1 (en) * | 2006-09-15 | 2008-03-20 | Pfizer Products Inc. | Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors |
-
2008
- 2008-04-11 AU AU2008239596A patent/AU2008239596B2/en not_active Ceased
- 2008-04-11 JP JP2010503085A patent/JP2010523681A/ja active Pending
- 2008-04-11 MX MX2009010815A patent/MX2009010815A/es active IP Right Grant
- 2008-04-11 US US12/595,233 patent/US20100209340A1/en not_active Abandoned
- 2008-04-11 EA EA200970936A patent/EA018964B1/ru not_active IP Right Cessation
- 2008-04-11 NZ NZ579945A patent/NZ579945A/en not_active IP Right Cessation
- 2008-04-11 CN CN200880018758A patent/CN101711249A/zh active Pending
- 2008-04-11 BR BRPI0810175-2A2A patent/BRPI0810175A2/pt not_active IP Right Cessation
- 2008-04-11 KR KR1020097023146A patent/KR20090130104A/ko not_active Application Discontinuation
- 2008-04-11 CA CA002683820A patent/CA2683820A1/en not_active Abandoned
- 2008-04-11 EP EP08742864.5A patent/EP2142544B8/en active Active
- 2008-04-11 UA UAA200911451A patent/UA101315C2/ru unknown
- 2008-04-11 ES ES08742864T patent/ES2425068T3/es active Active
- 2008-04-11 MY MYPI20094194 patent/MY150747A/en unknown
- 2008-04-11 WO PCT/US2008/004807 patent/WO2008127712A1/en active Application Filing
-
2009
- 2009-09-23 ZA ZA200906648A patent/ZA200906648B/xx unknown
- 2009-09-24 TN TNP2009000389A patent/TN2009000389A1/fr unknown
- 2009-09-29 IL IL201209A patent/IL201209A0/en unknown
- 2009-10-09 DO DO2009000242A patent/DOP2009000242A/es unknown
- 2009-10-09 SV SV2009003389A patent/SV2009003389A/es not_active Application Discontinuation
- 2009-10-09 NI NI200900183A patent/NI200900183A/es unknown
- 2009-10-30 MA MA32314A patent/MA31336B1/fr unknown
- 2009-11-09 EC EC2009009722A patent/ECSP099722A/es unknown
- 2009-11-09 CO CO09126919A patent/CO6241119A2/es not_active Application Discontinuation
- 2009-11-09 CR CR11098A patent/CR11098A/es unknown
-
2010
- 2010-07-07 HK HK10106576.7A patent/HK1139941A1/xx not_active IP Right Cessation
-
2013
- 2013-01-03 US US13/694,772 patent/US20130343988A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MA31336B1 (fr) | 2010-04-01 |
EA200970936A1 (ru) | 2010-02-26 |
IL201209A0 (en) | 2010-05-31 |
CA2683820A1 (en) | 2008-10-23 |
US20100209340A1 (en) | 2010-08-19 |
UA101315C2 (ru) | 2013-03-25 |
HK1139941A1 (en) | 2010-09-30 |
AU2008239596B2 (en) | 2013-08-15 |
MX2009010815A (es) | 2009-10-29 |
US20130343988A1 (en) | 2013-12-26 |
CO6241119A2 (es) | 2011-01-20 |
JP2010523681A (ja) | 2010-07-15 |
DOP2009000242A (es) | 2010-04-30 |
EP2142544B8 (en) | 2013-07-03 |
ES2425068T3 (es) | 2013-10-11 |
AU2008239596A1 (en) | 2008-10-23 |
EP2142544B1 (en) | 2013-05-22 |
TN2009000389A1 (en) | 2010-12-31 |
NZ579945A (en) | 2012-05-25 |
NI200900183A (es) | 2010-10-05 |
CR11098A (es) | 2010-01-27 |
CN101711249A (zh) | 2010-05-19 |
EP2142544A1 (en) | 2010-01-13 |
WO2008127712A1 (en) | 2008-10-23 |
EA018964B1 (ru) | 2013-12-30 |
KR20090130104A (ko) | 2009-12-17 |
SV2009003389A (es) | 2010-04-27 |
MY150747A (en) | 2014-02-28 |
ZA200906648B (en) | 2010-04-28 |
BRPI0810175A2 (pt) | 2014-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP099722A (es) | Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer | |
UY31254A1 (es) | Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones | |
CO6620050A2 (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
CR20140548A (es) | Derivados de aril-sultamo como moduladores de rorc | |
SV2010003598A (es) | Derivados de tiazol usados como inhibidores de pi 3-cinasa | |
UY29781A1 (es) | Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos | |
ECSP109856A (es) | Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842 | |
ECSP13012611A (es) | Derivados de pirazol-aminopirimidina como moduladores de la lrrk2 | |
CR20120130A (es) | Compuestos de benzoxepina inhibidores de la pi3k y métodos de uso | |
UY30498A1 (es) | Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones | |
CR20120414A (es) | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos | |
UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
CU20110145A7 (es) | Derivados de sulfonamida | |
UY31918A (es) | Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento | |
NI201000004A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
UY31127A1 (es) | Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841 | |
UY30282A1 (es) | Compuestos quimicos | |
CU20110078A7 (es) | Compuestos de carbazol | |
UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
ECSP13012596A (es) | Proceso de elaboración para derivados de pirimidina | |
UY31048A1 (es) | Nuevos compuestos de pirimidina y usos de los mismos | |
BR112012029647A2 (pt) | novos derivados de pirimidinas | |
ECSP099751A (es) | Derivados de 9-(pirazol-3-il)-9h-purin-2-amina y 3-(pirazol-3-il)-3h-imidazo[4,5-b]piridin-5-amina y su uso para el tratamiento del cáncer | |
DOP2009000200A (es) | Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pimiridina como inhibidores hsp-90 para tratar el cancer |